A Monumental Breakthrough in the Fight Against HIV/AIDS
In a groundbreaking scientific achievement, Immunotech Laboratories, Inc. proudly announces the successful completion of Phase III clinical trials for its patented immunotherapy treatment, ITV-1-ImmunH, offering a beacon of hope for patients battling HIV/AIDS.
Exceptional Clinical Outcomes
Conducted at the renowned Specialized Hospital for Active Treatment of Infectious and Parasite Diseases in Sofia, Bulgaria, these rigorous trials employed cutting-edge clinical methods, yielding remarkable results. Data from the final report paints a picture of significant immune system enhancements, including a surge in the absolute count of lymphocytes (LY), CD3 T cells, CD4 T cells, CD8 T cells, B lymphocytes (B Ly), and natural killer (NK) cells.
Equally impressive was the increase in the percentage of CD3 T cells, CD4 T cells, CD8 T cells, B Ly cells, NK cells, and a favorable shift in the CD4/CD8 ratio. These positive shifts in immune markers are crucial indicators of the body’s ability to combat HIV/AIDS.
Most notably, viral load measurements in approximately 80% of patient blood samples revealed non-detectable levels after completing the treatment cycles, a testament to the remarkable efficacy of ITV-1-ImmunH in suppressing the virus.
Furthermore, the treatment demonstrated a positive impact on opportunistic infections, exhibited compatibility with other antiviral medications, and was exceptionally well-tolerated by all patients, with no adverse side effects reported.
A Path to Commercialization
Immunotech Laboratories BG-Europe, a subsidiary of Immunotech Laboratories, Inc., has initiated the process of obtaining a permit for mass use (Phase IV) in Bulgaria. The company anticipates a favorable outcome, paving the way for the commercialization of ITV-1-ImmunH.
To facilitate this commercialization, Immunotech Laboratories, Inc. has entered into an agreement with a California-based Contract Manufacturing Organization (CMO) to produce the immunotherapy treatment. This collaboration is a crucial step in meeting the approval requirements of the Bulgarian regulatory authority.
In a strategic move to establish a long-term presence in Bulgaria, Immunotech Laboratories, Inc. and Immunotech Laboratories BG-Europe are embarking on the construction of a manufacturing facility in the country. This project, initiated in the fourth quarter of 2017, will ensure a stable and reliable supply of ITV-1-ImmunH.
The company’s research and development efforts continue at its laboratory in Monrovia, California, where scientists are exploring additional applications for its patented immunotherapy treatments.
A Commitment to Patient Well-being
Immunotech Laboratories, Inc. acknowledges past actions that may have inadvertently eroded trust among its shareholders. However, the company has relentlessly pursued every available avenue to rectify the situation and move forward with its mission of developing life-saving treatments.
Harry H. Zhabilov, CEO of Immunotech Laboratories, Inc. and the visionary behind the patented treatment, expressed his gratitude for the unwavering support of the company’s shareholders.
Zhabilov emphasized, “The successful completion of the Phase III trials is a testament to the dedication and expertise of our team. We are confident that ITV-1-ImmunH has the potential to revolutionize the treatment of HIV/AIDS and improve the lives of countless individuals worldwide.”
About Immunotech Laboratories
Immunotech Laboratories is a pioneering drug development company dedicated to harnessing the power of its proprietary proteins to combat debilitating infectious diseases. The company’s unwavering commitment to scientific innovation and patient well-being drives its pursuit of groundbreaking treatments.
Immunotech’s flagship product, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), a substance derived from porcine pepsin. Extensive research has demonstrated IPF’s remarkable ability to modulate the immune system, offering a promising approach to treating HIV/AIDS.
Safe Harbor Statement
This press release contains forward-looking statements that involve inherent risks and uncertainties associated with financial projections, clinical development timelines, regulatory approvals, and other factors. Immunotech Laboratories, Inc. cautions readers that these forward-looking statements are based on the company’s current beliefs and expectations, and actual results may differ materially from those projected.
Immunotech Laboratories, Inc. undertakes no obligation to update or revise any forward-looking statements contained in this release, whether as a result of new information, future events, or otherwise.
IR Contact
Harry Zhabilov
120 W Pomona Ave
Monrovia, CA 91016
Phone: (626) 538-4779
Fax: (626) 538-4779
